Welcome to our dedicated page for Rocket Pharmaceu SEC filings (Ticker: RCKT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Rocket Pharmaceuticals, Inc. (RCKT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed, late-stage biotechnology company, Rocket uses SEC reports to communicate material information about its gene therapy pipeline, financial condition, governance and significant corporate events.
Investors can use this page to locate current reports on Form 8-K, which Rocket files to describe events such as financial results, strategic corporate reorganization and pipeline prioritization, clinical trial developments and regulatory milestones. Recent 8-K filings referenced in available information include announcements of quarterly financial results, FDA acceptance of the resubmitted Biologics License Application (BLA) for KRESLADI in severe leukocyte adhesion deficiency-I (LAD-I), lifting of the clinical hold on the pivotal Phase 2 trial of RP-A501 for Danon disease, and leadership or board changes.
In addition to 8-Ks, users can access Rocket’s periodic reports on Forms 10-K and 10-Q, which provide more detailed discussions of its AAV and lentiviral gene therapy programs, risk factors and financial statements. These filings help explain how Rocket is prioritizing its AAV cardiovascular platform—covering Danon disease, PKP2-arrhythmogenic cardiomyopathy and BAG3-associated dilated cardiomyopathy—while advancing regulatory activities for KRESLADI and pausing additional internal investment in certain other programs.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, such as clinical and regulatory updates, restructuring plans, and changes in executive leadership. Real-time EDGAR updates allow users to see new Rocket filings as they are posted, while Form 4 insider transaction data and proxy materials can be reviewed to understand equity awards, inducement grants and governance practices. This page serves as a focused entry point for analyzing how Rocket’s SEC disclosures relate to the development and potential commercialization of its rare disease gene therapy portfolio.
Rocket Pharmaceuticals insider Martin Wilson has filed a notice to sell 12,253 common shares. The shares were recently acquired through restricted stock vesting on 02/11/2026 as compensation from the issuer. The planned sale through Fidelity Brokerage Services LLC has an aggregate market value of $40,583.16 and is listed for trading on NASDAQ, with an approximate sale date of 02/13/2026. The filing notes that 108,222,228 common shares were outstanding, and also discloses a prior sale of 1,646 shares for $4,909.69 on 11/18/2025.
Maverick Capital and related entities filed an amended Schedule 13G reporting their beneficial ownership of Rocket Pharmaceuticals common stock. They report beneficial ownership of 2,513,110 shares of Rocket, representing 2.3% of the outstanding common stock, based on 108,222,228 shares outstanding as of October 31, 2025.
The shares are held for Maverick’s investment advisory clients, including Maverick HP, L.P. with 1,917,698 shares and certain separately managed accounts with 595,412 shares. The filers certify that the securities were not acquired to change or influence control of Rocket Pharmaceuticals.
Shah Gaurav reported acquisition or exercise transactions in a Form 4 filing for RCKT. The filing lists transactions totaling 1,156,676 shares. Following the reported transactions, holdings were 870,648 shares.
Rocket Pharmaceuticals officer John Militello received new equity awards. On February 11, 2026, he was granted 29,982 shares of common stock at a price of $0, increasing his directly held common stock to 95,902 shares.
He was also granted a stock option covering 45,018 shares at an exercise price of $3.24 per share. Both the restricted stock units and the option vest one-third on February 11, 2027, with the remaining portions vesting in equal quarterly installments over the following two years, subject to continued employment.
Rocket Pharmaceuticals General Counsel Martin Wilson received new equity awards. On February 11, 2026, he was granted 311,813 shares of common stock in the form of restricted stock units at a price of $0 per share, bringing his directly held common stock (including RSUs) to 695,629 shares.
He was also granted a stock option for 468,187 shares at an exercise price of $3.24 per share, expiring February 11, 2036. One-third of both the RSUs and the option will vest on February 11, 2027, with the remaining portions vesting in equal quarterly installments over the following two years, contingent on continued employment.
Rocket Pharmaceuticals’ Chief Medical Officer Syed Ali-aamir Rizvi received new equity awards. On February 11, 2026, he was granted 61,963 shares of common stock in the form of restricted stock units at $0 per share, bringing his directly held common stock (including RSUs) to 407,874 shares.
He was also granted a stock option covering 93,037 shares of common stock with an exercise price of $3.24 per share. For both the RSUs and the option, one-third vests on February 11, 2027, with the remainder vesting in equal quarterly installments over the following two years, contingent on continued employment.
Stevens Christopher James reported acquisition or exercise transactions in a Form 4 filing for RCKT. The filing lists transactions totaling 155,000 shares. Following the reported transactions, holdings were 93,037 shares.
Rocket Pharmaceuticals executive Sarbani Chaudhuri received new equity awards in the form of stock options and restricted stock units. On February 11, 2026, she was granted 125,924 shares of common stock as RSUs at a price of $0, increasing her directly held common stock to 285,160 shares.
She also received a stock option covering 189,076 shares of common stock at an exercise price of $3.24 per share. For both the RSUs and the option, one-third will vest on February 11, 2027, with the remaining portions vesting in equal quarterly installments over the following two years, contingent on continued employment.
An affiliate of RCKT filed a Rule 144 notice to sell 12,279 shares of common stock through Fidelity Brokerage Services, with an aggregate market value of $40,669.28. The shares were acquired via restricted stock vesting on 02/11/2026 and the approximate sale date is 02/13/2026.
The notice states that 108,222,228 shares of the issuer’s common stock were outstanding. Over the prior three months, the same seller disposed of 6,276 shares of common stock for gross proceeds of $18,720.05. The filer represents they are not aware of undisclosed material adverse information about the issuer.
Rocket Pharmaceuticals shareholder Jonathan D. Schwartz has filed to sell 14,508 shares of common stock. The planned sale, through Fidelity Brokerage Services, has an aggregate market value of $48,051.95, with an approximate sale date of February 13, 2026 on NASDAQ.
The 14,508 shares were acquired on February 11, 2026 via restricted stock vesting from the issuer as compensation. Schwartz previously sold 2,545 common shares on November 18, 2025 for gross proceeds of $7,591.22. Shares outstanding were 108,222,228 at the time referenced.